WinstonWınston
Avantor logo

Avantor

AVTR
24
Medical - Instruments & Supplies · Healthcare
Price
$11.07
-0.19 (-1.69%)
Market Cap
$7.56B
Winston Score
24
Winston is worried
Weak fundamentals across most pillars.

Share count rising — dilution

+13.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 599.6M (2021) → 679.3M (2025)

Avantor makes and sells the materials, chemicals, and equipment that scientists need to do their work. Its customers are pharmaceutical companies, biotech firms, hospitals, and university labs. The company supplies things like lab chemicals, filters, and single-use plastic components used in drug manufacturing and research.

Avantor earns money by selling these supplies and materials directly to customers, often through long-term contracts and repeat orders. It operates globally, with a large presence in North America and Europe, and generates roughly $6–7 billion in annual revenue. Its competitive edge comes from deep relationships with drug manufacturers and a broad product catalog that makes it easier for customers to buy from one supplier rather than many. The main risk right now is weak demand from biotech and pharmaceutical customers, who have been cutting spending since the post-pandemic boom ended, which is reflected in the company's current negative operating margin.

Winston Score History

Politician Trades

5 trades / 12mo

1 Congressional buy and 4 sells on AVTR in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+0.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-32.5% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

3.1%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$279M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Avantor is growing revenue at 0% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
31.7%
Modest — 31.7% gross margin
Operating Margin
7.3%
Modest — 7.3% operating margin
ROCE
2.0%
Weak — 2.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-2.0%
Shrinking sales (-2.0% YoY)
EPS YoY
-175.9%
Earnings shrinking (-175.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
6.7%
Modest free cash flow (6.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.01
Conservative — low debt load (0.01)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial